ArticleCurrent issues in molecular biology2026
Urinary and Recombinant Follicle-Stimulating Hormone in Supporting Primate Follicular Development In Vitro.
Article in Current issues in molecular biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Urinary and recombinant follicle-stimulating hormone (FSH) are used clinically for ovarian stimulation. However, data on the efficacy of these two products are inconsistent. To examine the direct effects of urinary and recombinant FSH on follicular development and function, experiments were conducted using in vitro follicle maturation approach. Preantral follicles were isolated from ovaries of rhesus macaques and randomly assigned to three groups for individual culture, including recombinant human FSH alpha (rFSHa) and beta (rFSHb) and urinary human FSH (uFSH) supplementation. Follicle survival, growth, and cell-specific gene expression, as well as media estradiol, progesterone, and anti-Müllerian hormone (AMH) concentrations, were assessed. At week 5, antral follicle survival rates were higher in the uFSH group than rFSHa and rFSHb groups. Percentages of follicles with a diameter of >1 mm were greater in the uFSH than rFSHa group. Media concentrations of estradiol, progesterone, and AMH were comparable among groups. Bone morphogenetic protein 15 and growth differentiation factor 9 mRNA levels were higher in rFSHb-treated than rFSHa-treated follicles. Data suggest that, although in vitro follicle maturation can proceed despite FSH sources, urinary and recombinant protein preparations exhibit preferable effectiveness in supporting different aspects of folliculogenesis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.